Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Profitable or not, if PGM is making $20M in annual revenue, this stock will be worth nearly 0.05, conservatively, since I am even assuming the OS will double, which is very unlikely.
Please read my sticky if you haven't already.
GCEI
Great post bill, sorry for my delayed response.
I am on your bandwagon for sure. The new deal may not be immediately pleasing to current shareholders but I can definitely see it becoming far-superior to anything TPS by itself could offer.
TPS and the business it has generated for PXYN is not necessarily off the table, either - which I believe may have been a broad assumption by everyone here. The company may very well continue servicing it's well-established WC customer-base as the ball begins rolling with NHS.
PXYN
Can someone sticky this post?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110375432
Thanks, Neo, my pleasure guys.
This has always been a great board - very fitting of the underlying company; I'm glad that I could be of use.
EDXC
Yes, very true.
I thought an earlier presenter did well given the technical difficulties of the host but Todd really responded extremely well to this.
Excellent presentation and very encouraging information as well. Huge things are coming here this year.
EDXC
EDXC Webinar INFO
-- not written word for word and only as was possible to keep up
-- slides at bottom
M3CBD Vape will be introduced in February
Greenleaf $150K revenue thus far
-- dispensary and grow licenses for certain customers
O/S: 212M (I believe he said)
Float: 105M
Over several thousand shareholders, increased 5x over last 2 months
MMJ market:
-- Transparent side is est. to be $2.7B in 2014
-- Will expand into the newly licensed states
-- Est. $30-50B within next 10 years; enough business for most if not all of the current businesses to expand into
Pure:
-- 100 day pilot program
-- Communicating w/ marijuana enforcement for guidance on compliance w/ Autospense (see slide)
-- Final engineering inspection taking place today/tomorrow at PURE
-- After testing, they call in M.E.D. for inspection before going live
-- Vault-like, 800lb machine cannot be breached, reduces labor, wait-time, etc. (see slide)
VUZI:
-- Partnership for headset includes barcode scanner, real-time integration w/
-- Uplisted to NASDAQ yesterday w/ help of the IR (same for EDXC)
-- Received $25M funding from Intel
Questions & Answers (improvised as best as possible):
-- Sorry I spent a while laughing my ass off cause the host of these webinars has been messing up all day. We had 30 min of him fumbling around at the start of a different presentation at 11:00 ... he is having technical "diffidies"
What space are you currently operating in?
We've concentrated in Colorado, Canada, Washing, California, Nevada. Focus compliance.. will start generating revenue in all of those states this year.
What are some hurdles to acquiring business contacts and increasing revenue?
Establishing business contact is the easy part. Getting to the point where you are operating the business is difficult. There is a lot of white noise and chaos in the undustry right now. When we negotiate a contract, it may not come to fruition for 90 days or so, and it is less efficient than we'd like. Our business contacts are serious people who want to be successful.
What other cloud-based software companies are your competition?
Our system can be used in conjunction with our perceived competitors.
Biotrack THC, a friendly competitor
MJ Freeway, provides services that are also in our system
We look at all of them not necessarily as competitors, they all bringing tech to the market. We have not seen anyone else provide a total solution where we can plug into all of them.
What sets you apart?
Security. It is very important to protect patient and company data. Our engineering team is well-versed in software security. We are able to provide HIPAA compliance and auditing controls that truly protects patient, company, and regulatory data.
Todd (freestyling while host of webinar fucks around): "The m3Hub system is built to be highly-intuitive, allowing users to build their own unique systems within a system. Whatever you put into the mobile system can be tracked and controlled in real-time."
"Tracking/compliance will only get more expensive as the market grows."
Todd, freesytle: With filing of the audit, we've been establishing relationships with people/institutions across the country who want to work with us to fund our plans. These are critical accomplishments while will properly fund the company as we move into the revenue stage of the company. Development has cost less than sales and marketing will.
Todd's Closing: "EDXC in comparison is a major contender in the industry. We will stay on top of the technological side of the sector and, as for the consumables, we will provide the absolute safest and complaint products that we can."
Slides:
Quote from user: Penny Stock Barron
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110381649
Michael short developed M3HUB for EDXC he is the great grandson of Alexander Grand Bell are you kidding me and created the original DVR for Bill Gates!It is now obvious that EDXC is a sector leader we have the most complex tracking in the space with M3HUB, Autospense will soon be backed by the MED in Colorado,M3CBD is premium imported nutrient rich Eco farmed CBD oil from Europe not china.
EDXC
EDXC CEO, Todd Davis, talking now on live webinar:
Cannabis investors, analysts, executives, media, and consumers who would like to attend our free online webcast please click on the link www.cannawebcast.com/ and visit the Registration Page and to view the recording of the webcast please click on this link Cannabis Investor Webcast Recordings two weeks after the presentation.
TODD DAVIS TALKING NOW ON WEBCAST:
Cannabis investors, analysts, executives, media, and consumers who would like to attend our free online webcast please click on the link www.cannawebcast.com/ and visit the Registration Page and to view the recording of the webcast please click on this link Cannabis Investor Webcast Recordings two weeks after the presentation.
I betcha most sells here are just people selling a small portion, trying to lock in their gains. What they are also doing it locking out future gains.
The O/S is getting so tightly wound up into strong hands it's practically disgusting to watch.. knowing that its going to literally fly off the handle on any meaningful news.
Not to sound pumpy but this is still way too undervalued and incredibly tight. News is going to start a fire, better buy some extinguishers if you don't have any handy.
RXMD
It's not far-fetched to think they can get back to the OTCQX via uplist given that the company is stronger than even before, haha.
$RXMD i smell an uplist coming
There--are many--reasons to--expect stellar--revenues this--January.
1) This year's seasonal flu reached epidemic levels at the very end of December.
-- In addition to running a brick-and-mortar store, RXMD specializes in health risk management and provides medicine to long-term (senior) care facilities. Seniors happen to be one of the primary recipients of flu medicines.
http://www.newsweek.com/flu-has-reached-epidemic-levels-cdc-says-296122
2) The PharmCo pharmacy has recently been renovated. They also increased and improved their sales staff and methods.
http://finance.yahoo.com/news/progressive-care-releases-open-letter-140000795.html
http://finance.yahoo.com/news/progressive-care-inc-pharmco-fills-140000895.html
-- This all happened before started reporting again. We inherited it in great shape to begin with.
-- The reward for their efforts was quickly recognized, providing record sales in December and proving it to be both effective and cost-efficient. There is no reason to think that the growth trend will suddenly stop shortly after the adoption of new policies, in fact, as they work out the kinks and bottle-necks in their new operating procedures, they should continue to improve, potentially at an even faster rate.
3) The partnership with Caremed is bound to increase revenue and reduce the cost of operations.
http://finance.yahoo.com/news/progressive-care-announces-co-joint-180000223.html
-- Caremed has a similar business model as PharmCo and, through their mutually-beneficial partnership, both companies can take advantage of economies of scale while saving on expenses/services that will overlap. This development alone may be enough to send the company net profitable during Q1. Combined with the fact that (at this rate) all the liabilities are going to be settled with a max OS around 100M, there will be no further need to dilute in a way that will hurt shareholder value (more on this later)
-- It is of note that Caremed is the larger company, with a higher average prescriptions per month during 2014. RXMD may stands to gain slightly more from the exchange of equity in each business, which was equal.
3) RXMD's parnership with "Health Care of South Florida" will boost the growth of the highly-lucrative health care management and long-term care facility business where, by the way, the market for such services is enormous.
http://finance.yahoo.com/news/progressive-care-announces-alliance-health-143000526.html
-- Improved efficacy and safety resulting from this partnership will significantly add value to RXMD's service for any property/business manager.
-- This alliance created a new, direct link between RXMD and the target consumers - which Health Care of South Florida already works with - instantly increasing market share.
4) RXMD's plan to move into non-sterile compound pharmaceuticals, an extremely high-margin niche of the pharmaceutical industry.
-- One of the key barriers to growth in this niche is the need for consistent cash flow, especially if the business volume is ballooning. The recent elimination of liabilities (via the agreement with Tarpon) will make it much easier for the company to obtain a revolving line of credit to use toward their cash flow needs, allowing the business to explode in a relatively short period of time.
-- The above point means no further share issuance unless it is a great acquisition or business play that will only benefit the shareholders.
There is so much going on here with RXMD. It is extremely undervalued using very conservative metrics to estimate the price target of 0.11 without accounting for the majority of what is written above or any level of profitability/growth which will more than likely be seen at some point, perhaps early this year.
See conservative price target and comparison in this stickied post:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110162555
Here is an excellent article which supplements all of the above information well:
http://www.microcapdaily.com/progressive-care-inc-otcmktsrxmd-making-moves/18524/
RXMD
The float is held tightly by investors who know it is still undervalued.
Can't wait for record revenues - which we know are coming - to propel this to new highs.
RXMD
All those catalysts combined will place this at least in the .20s short/medium-term.
RXMD
Listening to the webcast right now.. Can't wait to hear EDXC blow it out of the water compared to the others here.
Last presentation was on distilling oils. EDXC has this covered.
Current discussion is on compliance. EDXC has this covered.
EDXC is major leaps ahead of the current presenters and is not a one trick pony either!
Yeah, I could not agree more.
I almost feel bad for those selling out here. Maybe if they are taking a little profit and letting most ride but only makes sense if done patiently
on the ask.
All shares sold here will be worth at least double shortly.
January revenue number comes out ; it will be hard to buy anything under 0.2 imo... 2 days away from feb
Nice churn yet again today.
Can't wait for January revenue numbers and 2015 revenue guidance to hit.
RXMD
Another excellent day. Great churn ad usual. Nice movement. Stealth bulls all over this thing. I said weeks ago and last week that we'd all be kicking ourselves for not buying more in the 1s/2s/3s/4s/5s... was I lying? Fu<k no.
I never lie. Soon we may be kicking ourselves for not buying sub .10
Watch. See my sticky.
Why are there like 100 uploads?
GCEI
Great! Thanks for letting the board know.
Any chance you can make copy-pasta of the uploaded "news release"?
I am on a trip and only have my phone..
That's a really well written article which provides a ton of encouraging facts for prospective and current investors. Thanks for posting it here.
Reading it actually revamped my confidence, reminding me why I bought this and the fact that the recent share-price appreciation is only the beginning for this gem. There are so many awesome aspects of RXMD, including their charitable food drives, which make this a no-brainer even at the current, extremely undervalued but relatively "high" recent price of only 0.05.
RXMD
Article below for future preservation:
http://www.microcapdaily.com/progressive-care-inc-otcmktsrxmd-making-moves/18524/
Progressive Care Inc (OTCMKTS:RXMD) continues to move up on accelerating volume recently hitting $0.05 a share after breaking out over a penny from sub penny land.
In recent news the Company announced a new medication monitoring and health safety program with Health Care of South Florida. The program is a vital step in managing the health and wellness of patients with chronic illnesses.
Health Care of South Florida is a home health care agency whose licensed nurses are trained to assess health care risks within the patient’s home. Through the collaboration and communication with the patient and his or her primary care physician, a licensed nurse from the program will conduct a comprehensive review of the patient’s health situation including medical records, medications and whether there are injury risks in the home based on the patient’s condition.
Progressive Care Inc (OTCMKTS:RXMD) operates through its subsidiary PharmCo, LLC as a brick and mortar South Florida provider of prescription pharmaceuticals. The Company specializes in health practice risk management, the sale of anti-retroviral medications and related medication therapy management, the sale and rental of durable medical equipment (“DME”) and the supply of prescription medications to long term care facilities.
RXMD has been doing some EPIC revenues reporting $8,318,422 in sales for the 9 months ended September 30, 2014 up from $6,634,317 for the same period last year. These kind of numbers put RXMD Into a small elite group of bb’s that are doing over $10 mm in annual sales.
The Company said on January 5 that December 2014 sales increased by approximately 35% over December 2013. Over 14,000 prescriptions were filled in the month, of which over 40% were new. This represents the 6th month in 2014 that PharmCo achieved record setting sales results.
The Elephant in the room on RXMD had been their inability to get their filings completed which resulted the stock going from fully reporting OTCBB to Pink Sheets with the yield designation from OTCMarkets. This along with debt holders converting their paper resulted in a seriously depressed stock price.
RXMD said in a letter to shareholders on December 29 ”In September, we took a great leap forward in this regard by filing our unaudited year-end financial statements for 2012 and 2013 through OTCMarkets. These financial statements were then quickly followed up by the filing of our unaudited financial statements for all three quarters of 2014 on November 22nd. The filings not only presented the company’s current financial position to the public, but also presented the great strides the company has made towards achieving profitability by reducing operating costs and liabilities and increasing sales.
The Company did not say if they are seeking full OTCBB listing and will remain fully reporting or if they will continue to report but continue to trade on the pinks. In any case I imagine they are working hard to get the yield designation removed.
RXMD also addressed the debt issue ”’In August, we reached our first major accomplishment of the year. After months of negotiation and hard work, the company finalized our debt exchange transaction with Tarpon Bay Partners, LLC. Through the execution of the deal with Tarpon Bay and approval by the Circuit Court for the 3(a)(10) transaction to proceed, the company will be able to eliminate approximately $1.8 million in debt off of its balance sheet in the coming year. This transaction allowed the company to settle its litigations with creditors and note holders and has significantly improved our cash flow.
RXMD covered a lot more in their letter to shareholders on December 29, key highlights were ”agreement and court approval to execute a 3(a)(10) transaction through Tarpon Bay Partners, LLC to eliminate $1.8 million in debt in the coming year.-Filed unaudited financial statements with OTCMarkets through the most recent completed quarter.-Restructured management, aggressively cut costs and began a hiring program to recruit talent and meet growing demand and renovated their PhamCo facility.-Increased filled prescription counts by approx. 50% from 8,500 scripts per month to almost 13,000 and Increased pharmacy sales by 35% to $8.1 million through September 30, 2014
RXMD finished off the letter by saying ”As we enter into 2015, we will look to take advantage of our marketing efforts with doctors’ offices, clinics, and hospitals, as well as seek licensures in additional states in order to begin positioning PharmCo as a national brand. We will develop our new non-sterile compounding department which carries much higher gross margins than standard pharmaceuticals. We will also seek to expand our charitable presence in the community which currently includes weekly deliveries of food and necessary services to the local food bank and the less fortunate.”
Currently trading at a market valuation of just $547,000 according to OTCMarkets RXMD has been severally undervalued in recent months due to the filing issue as well as large blocks of new stock coming into the market as a result of the debt conversions.
Now that management has addressed these issues and seems to be aggressively moving forward the stars may be aligned for RXMD; after all this is a Company on track to top $10 million in annual revenues and the street is starting to notice as evidenced as the fast growing shareholder base currently accumulating. RXMD is a stock to watch.
Sweet news today. The phase 1 study results came pretty fast and were very encouraging.
I love how EDXC has a hand in almost every important aspect of the nascent marijuana industry without being spread too thin and, perhaps most importantly for the shareholders, without any significant dilution. All share issuances I have seen over the past 2 years have been well worth the increase in OS.
EDXC
I would definitely like to know why TPS gave up the Series D shares they earned. Can't wait to see what volume of sales NHS does Quarter-over-Quarter - w/ results for Q2 without TPS.
PXYN
Hello again, JPerdue2.
INQD
Trading will begin in 3-6 weeks.
INQD
Nice to know EDXC is not goofing around when it comes to partners.
EDXC
Great points, I can hardly wait to watch her fly on any of that related news.
Adding at these levels is a no-brainer Stock Jock.. Once news starts coming in EDXC will move up very fast as the float is locked and no one will be selling. I'm Expecting updates on audit, MED Inspection at pure dispensary Or if were lucky news about the CBD trials for Neuropathy patents in Missouri as I believe CBD will be The number one health supplement in America Very soon!!
Triple bounce at low of 4.20 this year
Coincidence or not, there is not much room to go lower. Haha.
EDXC
Rescheduling seems to be just on the horizon here.
Lots of major catalysts coming, Ty.
The sector was taking a nap but it will return before 2016 and stronger than ever before as marijuana becomes a focal point of the nation's presidential campaigns.
EDXC
Great points. This non-diluting, constantly improving company is way undervalued here, IMHO.
EDXC
Yep .. NHS gets 64% of what is essentially net revenues generated directly through them. And 9% of the net revenue of sales PXYN makes by themselves or through other partners, like TPS.
But they are paid 55% only AFTER it is collected by PXYN it seems.
However, there is quite a comprehensive list of services they're offering and that will substantially CUT DOWN on total costs of the company -- leaving them to do what they do best: compound medical concoctions like the carnie flapjack man "churning 'em out like hotcakes".
Either way, we will have to wait until at least the filings from Q1/Q2,2015 (10-Qs) to really get an idea of how this changes things as compared to TPS.
Perhaps the increased production they will achieve by focusing on what they are good at, along with what may be a very large order volume for NHS, will more than make up for the temporary business from TPS (who may yet have contracts in the future)
PXYN
Brilliant 8-K here. Just finished reading it all..
Seems to be a bold move by the company.
We will no longer have to worry about:
-- a super-bloated SS (although it is still bloated, nothing an R/S can't fix before uplisting)
-- the complicated gross/net revenue structure along with factoring everything
It seems that NPHS will effectively:
-- massively help reduce the cost of general/administrative services
-- be responsible for the national expansion that we've been praying for
-- significantly simplify the objectives required to succeed:
------ financial tracking
------ consumer/physician/government regulatory relationships
------ sales/growth
-- render the in-house electronic billing system (PXYN was going to develop) obsolete/unnecessary
-- only be paid commission when they earn it and ONLY when PXYN gets paid
PXYN
I think that the undisclosed ask was intended to keep the current bullish ascent in check.. they want it to go up but don't want to let it get ahead of itself before PR/news.
RXMD
Another brilliant day, ladies and gentlemen.
Nice a steadily walking up, churning shares, and closing above the the 200MA for the first time.
New highs, new lows, and a very promising future here.. short, medium, and long-term.
RXMD
Nice churn here today in the 4s.
Consistently making higher highs and higher lows, relieving the weak hands of their shares, and tightening up the float as the big January revenues PR and guidance on this year's productivity and record revenue growth is possibly only a few days away now.
RXMD
True, they may easily be keeping a rolling count as the month progresses. Might just get the confirmed numbers for the first half or two-thirds of January to extrapolate for monthly revenues numbers by ourselves.
It all depends how they want to do it.
We know that they like to communicate with shareholders and that they will probably play the chart - as they know they are still undervalued here.
Good things on the horizon either way
RXMD
No problem mate. Asking questions is a good way to learn.
This being a pharmacy - not sure if they compound any of the drugs themselves (they likely do) - it may take a bit for them to consolidate all of their revenues together, given the fact that they often operate and collect revenues with account receivables (ARs). Additionally, they now have a partner pharmacy to tally the books of. Could take a while (say a few weeks) but we will likely get a preliminary estimate with confidence that it is close to what they will eventually file.
In this industry:
1/3rd of ARs collect in first 30 days
2/3rd in 60-90 days
last third within a year and they will generally sell the longer-term, high-risk ones to a factor for a discount (to keep their cash flows in order)
Given that this company is unlikely to do much factoring, I doubt we will see them struggle with cash flows as much as other pharmaceutical companies do.
RXMD
Early February would make sense. I'd say roughly 2-3 weeks.
RXMD
Agreed, the float is held tight here, with promising numbers we can fly off since few of us will be dumb enough to let go.
RXMD
You better believe it. Have you seen my sticky?
This is even better - in so many ways than the PXYN run - perhaps, best of all ORGANIC.
This baby might just go to 0.2x and hold.
RXMD